Opexa Therapeutics, Inc. OPXA
No live quote for OPXA yet.
- Market cap
- 7.43M
- Revenue (ttm)
- 2.29M
- Profit margin
- -232.31%
- EPS (ttm)
- -0.722
- Shares out
- 7.66M
- Forward P/E
- -4.41
- Volume
- 307.28K
- Avg volume
- 193.66K
- Open
- 1.15
- Previous close
- 1.07
- Beta
- 2.09
- Analysts
- Hold
- Price target
- 1.00
Key statistics
- Enterprise value
- 6.01M
- PEG ratio
- 0.00
- Price / sales
- 3.24
- Price / book
- 4.62
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -4.67M
- Total cash
- 1.82M
- Total debt
- 26.53K
- Return on equity
- -141.40%
- Short % of float
- 7.15%
- 50-day average
- 1.03
- 200-day average
- 0.761182
Analyst view
Consensus: hold
- Strong buy0
- Buy0
- Hold1
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.12.
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 27, 2016 | Aegis Capital | down | — | Hold |
| Oct 27, 2016 | Chardan Capital | down | — | Neutral |
| Nov 3, 2015 | Chardan Capital | init | — | Buy |
| May 25, 2015 | Maxim Group | init | — | Buy |
| May 29, 2014 | Aegis Capital | init | — | Buy |
| Mar 23, 2014 | Brinson Patrick | init | — | Outperform |
About Opexa Therapeutics, Inc.
Opexa Therapeutics, Inc., a biopharmaceutical company, develops personalized immunotherapy to treat multiple sclerosis (MS) and other autoimmune diseases based on its proprietary T-cell technology. The companys lead product candidate is Tcelna, a T-cell immunotherapy for the treatment of patients with secondary progressive MS. It is also developing OPX-212, an autologous T-cell immunotherapy that is in preclinical development to treat neuromyelitis optica. The company was formerly known as PharmaFrontiers Corp. and changed its name to Opexa Therapeutics, Inc. in June 2006. Opexa Therapeutics, Inc. was founded in 2003 and is headquartered in The Woodlands, Texas.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- opexatherapeutics.com
News
Your note
Sign in to keep a note on OPXA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BARABE TIMOTHY C | Director | Sale | Nov 17, 2016 | 12,910 |
| MADERIS GAIL J | Director | Acquisition (Non Open Market) | Sep 29, 2016 | 25,884 |
| RICHMAN MICHAEL | Director | Acquisition (Non Open Market) | Sep 29, 2016 | 25,884 |
| SEAMAN SCOTT B | Director | Acquisition (Non Open Market) | Sep 29, 2016 | 29,989 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Group, Inc. (The) | 1.08% | 82,450 | 51.12K | Jun 29, 2017 |
| CALPERS (California-Public Employees Retirement System) | 0.87% | 66,512 | 41.24K | Jun 29, 2017 |
| Geode Capital Management, LLC | 0.47% | 35,913 | 22.27K | Jun 29, 2017 |
| Two Sigma Securities, LLC | 0.38% | 28,734 | 17.82K | Jun 29, 2017 |
| Bank Of New York Mellon Corporation | 0.26% | 19,798 | 12.27K | Jun 29, 2017 |
| Virtu KCG Holdings LLC | 0.23% | 17,578 | 10.90K | Jun 29, 2017 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Extended Market Index Fund | 1.27% | 97,243 | 81.68K | Mar 30, 2017 |
| Fidelity Extended Market Index Fund | 0.46% | 35,198 | 21.82K | May 30, 2017 |
| Claymore ETF Tr-Wilshire Micro Cap ETF | 0.07% | 5,090 | 3.15K | May 30, 2017 |
| iShares Core S&P Total U.S. Stock Market ETF | 0.04% | 3,220 | 2.00K | May 30, 2017 |
| Fidelity Total Market Index Fund | 0.01% | 715 | 443 | May 30, 2017 |